Abstract:

Diabetic macular edema can cause damage to retinal cells and fibrosis, which is the leading cause of diabetic patients’ visual loss. The occurence and development of disease are related to the interaction of advanced glycation end-products, leukocyte stasis, vascular endothelial growth factor and other inflammatory factors. Targeted therapy for macular edema, such as nonsteroidal anti-inflammatory drugs, Ozurdex, lymphocyte functionassociated antigen-1, and so on,  has shown certain curative effect in clinical trials and provides new methods for the treatment of diabetic macular edema.  (Int Rev Ophthalmol,  2017,  41:   62-67)